



## Alcohol and Noncommunicable Diseases: Part I Cardiovascular Diseases, Obesity, Respiratory Diseases, Depression, Liver Diseases

Shashi K. Agarwal, MD \* 

<sup>1</sup>2227 US Highway 1, #309 North  
Brunswick, NJ 08902 USA



### Abstract

Alcohol is a popular drink and is consumed globally. It has received considerable scrutiny in its effect on health. Although its relationship with most cardiovascular diseases is J/U shaped, in general, alcohol intake can increase the risk of several diseases. Heavy intake may induce weight gain. Although no definite relationship has been noted with COPD, asthma, and lung cancer, it does appear to increase the propensity for the development of pneumonia. Its use is strongly related to chronic liver disorders. Its relationship with depression is bidirectional, and deleterious for both conditions. In general, alcohol intake of 2 drinks per day for men and 1 drink per day for women appears to be relatively safe.

Keywords: alcohol, non-communicable diseases, cardiovascular diseases, respiratory diseases, COPD, obesity, depression, liver diseases

Copyright : © 2021 The Authors. Published by Medical Editor and Educational Research Publishers Ltd. This is an open access article under the CC BY-NC-ND license (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

### 1 | INTRODUCTION

**N**on-communicable diseases (NCD) are chronic and may lead to prolonged disability and premature death<sup>1,2</sup>. It is estimated that NCDs are responsible for over 70% of total global deaths each year<sup>3</sup>. The majority of these occur in low- and middle-income countries<sup>4</sup> and a severe financial burden<sup>5</sup>. The Sustainable Development Goals hope to reduce by 2030 (relative to 2015 levels) premature mortality from NCDs by one third<sup>6</sup>.

The effects of alcohol on health can vary depending on the amount and pattern of intake<sup>7–9</sup>. In the United States, a standard drink contains 12–15 g of pure ethanol and this is present in 100–125 ml of wine, 240–300 mL of beer, and 30–37.5 mL of spirits<sup>10</sup>. Moderate alcohol intake is considered as two standard drinks a day for men and one standard drink a day for women<sup>11,12</sup>. Heavy drinking is defined as, high-dose intake, of >60 g/day in men and >40 g/day in women, usually taken over long term<sup>13</sup>. Binge drinking is considered as 4 or more drinks for women and 5 or more drinks for men over a 2-hours or in

one sitting<sup>14,15</sup>. Compulsive excessive alcohol intake may lead to alcohol use disorder (AUD)<sup>16</sup>. The National Institute on Alcohol Abuse and Alcoholism defines AUD as “a chronic relapsing brain disease characterized by an impaired ability to stop or control EtOH use despite adverse social, occupational, or health consequences”<sup>17</sup>. Although low to moderate alcohol intake may have some beneficial effects, alcohol consumption, in general, is associated with several negative health consequences<sup>18</sup>. Besides its impact on diseases mentioned in this manuscript, alcohol intake can cause cancers of the breast, mouth, throat, esophagus, liver, and colon<sup>19</sup>, learning and memory difficulties (including dementia)<sup>20,21</sup>, and mental health disorders, such as depression and anxiety<sup>20,22</sup>. Alcoholics tend to be more prone to trauma<sup>20,23</sup> and more likely to be involved in homicide, suicide, sexual assault, and violence<sup>24–27</sup>. Drinking alcohol during pregnancy can be extremely dangerous, and can increase the risk of miscarriage, stillbirth, or fetal alcohol disorder<sup>28–30</sup>. Alcohol poisoning is a medical emergency and is associated with extremely high blood alcohol levels<sup>31</sup>. The World Health Organization estimated that, in 2018, around 5% of global deaths were attributable to alcohol consumption<sup>32</sup>.

The health effects of alcohol on NCDs are discussed in this two-part manuscript. Part I discusses the relationship between alcohol intake and cardiovascular diseases (CVD), chronic obstructive pulmonary disease (COPD), depression, and liver diseases. Part II discusses its impact on cancer, diabetes mellitus, kidney diseases, Alzheimer’s disease, and arthritis.

---

**Supplementary information** The online version of this article ([10.52845/CMI/2021-2-3-5](https://doi.org/10.52845/CMI/2021-2-3-5)) contains supplementary material, which is available to authorized users.

---

**Corresponding Author:** *Shashi K. Agarwal, MD*  
*Shashi K. Agarwal, MD 2227 US Highway 1, #309*  
*North Brunswick, NJ 08902 USA*  
*Email: [usacardiologist@gmail.com](mailto:usacardiologist@gmail.com)*

## 2 | DISCUSSION

Cardiovascular diseases (CVDs) are an array of diseases that affect the cardiovascular system<sup>33</sup>. They include hypertension (HTN), coronary heart disease (CHD), stroke, heart failure (HF), cardiac arrhythmias, congenital heart disease, peripheral artery disease (PAD), vasculogenic erectile dysfunction (ED), and venous thromboembolism (VTE)<sup>33</sup>. They cause considerable morbidity and are the number one cause of mortality worldwide<sup>34,35</sup>. Almost one-third of all worldwide deaths are attributable to CVDs<sup>36</sup>. In 2016, chronic respiratory diseases were responsible for 7% of all global deaths<sup>37,38</sup>. Community-acquired bacterial pneumonia, although not an NCD, is strongly associated with alcoholism<sup>39</sup>. Pulmonary tuberculosis is also deleteriously affected by alcoholism<sup>40</sup>. Overweight refers to a BMI of 25–29.9 kg/m<sup>2</sup> while obesity exists when the BMI is  $\geq 30$  kg/m<sup>2</sup>.<sup>41</sup> Obesity affected 42.4% of the US population in 2017–2018<sup>42</sup>. Obesity is associated with several NCDs<sup>43,44</sup>, especially type 2 diabetes mellitus (DM) and CVDs<sup>45</sup>. Depression is a common cause of emotional suffering<sup>46</sup>. It is closely associated with anxiety<sup>47</sup>, dementia<sup>48</sup>, DM<sup>49</sup>, CHD<sup>50</sup>, Parkinson’s disease<sup>51</sup>, epilepsy<sup>52</sup>, pain<sup>53</sup>, several cancers<sup>54</sup>, osteoporosis<sup>55</sup>, and irritable bowel syndrome<sup>56</sup>. Chronic liver pathologies are also common<sup>57</sup>. The major chronic diseases affecting the liver are hepatitis B virus (HBV)<sup>58</sup> and hepatitis C virus (HCV) <sup>59</sup>infections, steatohepatitis due to non-alcoholic fatty liver disease<sup>60</sup>, alcoholic liver disease<sup>61</sup>, hepatic cirrhosis<sup>62</sup>, and primary hepatocellular carcinoma<sup>63</sup>.

The development and progression of NCDs are dependent on several modifiable and non-modifiable risk factors. Non-modifiable risk factors include heredity, age, race, and gender. Socioeconomic, cultural, political, and environmental factors may also play a role. The major modifiable factors include diet, obesity, physical activity, and non-smoking. Alcohol consumption is also a modifiable factor that impacts NCDs and is discussed in this manuscript.

## 2.1 | CARDIOVASCULAR DISEASES

Light to moderate alcohol intake has been associated with a lower risk of cardiovascular disease<sup>64</sup>. Heavy consumption has been associated with deleterious CV outcomes including increased mortality<sup>65</sup>. Studies have established that alcohol consumption and CVD have a J- or U-shaped relationship<sup>66</sup>. Harmful CVD effects are also noted with binge drinking<sup>67</sup> and alcohol use disorder<sup>68</sup>. About 5% to 24% of hypertension cases are associated with ethanol consumption<sup>69,70</sup>. It is estimated that intake of 3 to 4 drinks per day raises the prevalence of hypertension by 50%, when compared with non-drinkers, while an intake of 6 to 7 drinks per day, increases the prevalence by 100%<sup>71</sup>. Binge drinking, in the short term, raises the blood pressure from 4 to 7 mmHg systolic and 4 to 6 mmHg diastolic<sup>72-74</sup>. Reduction in alcohol intake to <2 alcoholic drinks per day helps reduce the blood pressure in a dose-response manner<sup>75</sup>. Most studies indicate that alcohol consumption between 2.5 g/day and 30 to 60 g/day (mild to moderate drinking) is cardioprotective for both CV mortality and CHD mortality<sup>76</sup>. In a meta-analysis done by Bagnardi and colleagues, the risk of CHD was higher in binge and heavy drinkers, when compared with non-drinkers<sup>77</sup>. A similar pattern has been noted between alcohol intake and stroke<sup>78</sup>. Larsson et al in a systemic review and meta-analysis of 27 prospective studies concluded that light to moderate alcohol consumption (1-2 drinks/day) was associated with a lower risk of ischemic stroke, whereas heavy drinking (>2-4 drinks/day) was associated with an increased risk, especially of hemorrhagic stroke<sup>78</sup>. HF also appears to be less in individuals consuming <7 drinks/week<sup>79</sup>. Wannamethee et al. found that heavier drinking ( $\geq 5$  drinks/day or  $\geq 35$  drinks/week) significantly increased the risk for HF<sup>80</sup>. Heavy alcohol intake may also induce alcoholic cardiomyopathy<sup>81</sup>. The causal relationship between alcohol intake and atrial fibrillation has also been known for a long time<sup>82</sup>. In a recently published study of 107,485 subjects followed for nearly 14 years, Csengeri et al. found that alcohol increased the risk of developing atrial fibrillation by 16%, irrespective of the type of beverage consumed<sup>83</sup>. According to Koskinen and group,

5%-10% of all new episodes of atrial fibrillation are related to alcohol use<sup>84</sup>. Alcohol also plays a significant role in sudden cardiac death (SCD)<sup>85</sup>. In a study of the Finnish population, 4 of 10 victims of unexpected SCD exhibited evidence of alcohol intake before the fatal event<sup>86</sup>. Drinking during pregnancy is also harmful to the offspring, who may be born with congenital anomalies such as aberrant great vessels, atrial septal defects, and ventricular septal defects<sup>87,88</sup>. High levels of alcohol intake are also associated with an increased risk of PAD<sup>89</sup>. Wang et al, in a meta-analysis, determined that light to moderate alcohol intake (<21 drinks/week) correlated with a decreased risk of erectile dysfunction<sup>90</sup>. Alcohol is also associated with many other CVD risk factors, such as sleep disorders<sup>91</sup>, chronic kidney disease<sup>92</sup>, weight gain<sup>93</sup>, depression<sup>94</sup>, and smoking<sup>95</sup>. The beneficial effects of alcohol are related to several actions<sup>96-104</sup>. Alcohol intake has an inverse association with T2DM (low to moderate intake)<sup>96</sup> and tends to increase HDL-C and apolipoprotein A-I<sup>97-99</sup> – these effects are CVD protective. Alcohol helps alter the atherosclerotic plaque composition and provides stabilization<sup>100</sup>. Alcohol also exerts several effects on factors involved in hemostasis, such as inhibition of platelet aggregation<sup>101</sup>, lowering of fibrinogen levels<sup>102</sup> and plasma viscosity<sup>103</sup>, as well as increasing levels of tissue plasminogen activator<sup>104</sup>.

## 2.2 | OBESITY

The relationship between alcohol intake and obesity has been well studied<sup>105,106</sup>. Several studies have however produced conflicting findings<sup>105,107</sup>. Since alcohol provides extra calories (1 gram of alcohol provides 7.1 kcal (29 kJ), its intake with a regular diet may lead to a positive energy balance, and weight gain<sup>108</sup>. It is estimated that in the US, 16% of adult drinkers' total energy intake comes from alcohol<sup>109</sup>. However, alcohol's relationship with obesity is not that simple<sup>110-112</sup>. Several studies show that light-to-moderate alcohol intake is not associated with weight gain<sup>105,108</sup>. Moderate drinkers are more likely to follow healthier lifestyles, such as exercising regularly and eating fruits and vegetables, which tends to prevent weight gain<sup>107,113</sup>. Heavy drinking does tend to be associated with an increased risk of obesity<sup>107</sup>.

A recent study confirmed that high alcohol consumption, especially binge drinking, was associated with higher risks of obesity in Korean men<sup>114</sup>. The increased tendency for men to gain weight with excessive alcohol drinking may be because they tend to drink about three times the amount of alcohol consumed by women and are more likely to drink beer and spirits<sup>115</sup>. Beer is rich in carbohydrates and may provide more calories<sup>108,116</sup>. Women tend to drink more wine, which is more likely to protect against weight gain<sup>105</sup>. Many other factors like socioeconomic status<sup>117</sup>, behavioral changes<sup>118</sup>, metabolic effects<sup>119</sup>, etc. may also play a role. The available data, however, does not conclusively confirm a positive association between alcohol consumption and weight gain<sup>105,120</sup>.

### 2.3 | RESPIRATORY DISEASES

There is no definitive association between alcohol intake and COPD, or lung cancer<sup>121–123</sup>. The association between alcohol abuse and pneumonia is, however, strong<sup>124–126</sup>. Although not an NCD, this association will be briefly discussed. AUD individuals are often affected by bacterial pneumonia with *Streptococcus pneumoniae* and *Klebsiella pneumoniae*<sup>127,128</sup>. These patients are more prone to bacteremia, sepsis, septic shock<sup>126,129</sup>, and adult respiratory distress syndrome (ARDS)<sup>130</sup>. ARDS is almost four times more likely to occur in AUD patients than nonalcoholic patients<sup>131,132</sup>. Its presence is associated with poorer outcomes, including persistent hospitalization and death<sup>133</sup>. Abusers of alcohol are not only less likely to receive preventive anti-pneumococcal vaccination<sup>134</sup> but may also experience a less protective response<sup>135</sup>. Individuals with AUD are also more likely to develop tuberculosis (TB)<sup>136</sup> and respiratory syncytial virus infection<sup>137</sup>. Acute lung injury is also seen more commonly in alcoholics after major trauma, such as a motor vehicle accident, gunshot wound, or burns<sup>138,139</sup>. Excessive alcohol consumption increases susceptibility to pneumonia through multiple mechanisms<sup>140–143</sup>. These include a reduced immunity<sup>140</sup>, altered microbial composition in the lung passages and alveoli<sup>141</sup>, and an increased risk of aspiration<sup>142</sup>. Several other factors are also known to play a deleterious role<sup>143</sup>.

### 2.4 | DEPRESSION

Alcohol misuse and depression commonly co-occur<sup>144,145</sup>. AUD individuals are many times more likely to have suffered from major depressive disorder<sup>146,147</sup>. Depression may also lead to alcohol abuse in some individuals<sup>148</sup>. The alcohol–depression relationship appears to be curvilinear, with alcohol abstinence and heavy drinking both being associated with a higher risk of depression<sup>149,150</sup>. Both conditions are interlinked and co-existence results in greater severity and a worse prognosis for both disorders than either condition independently<sup>151–154</sup>. Data indicates that men usually develop AUD before depression, while women develop depression and then progress on to AUD<sup>155,156</sup>. Patients who abuse alcohol may also exhibit more depression and tend to be not adherent to treatment<sup>157</sup>. Alcohol abstinence appears to significantly improve depressive symptoms in depressed individuals<sup>158</sup>. Antidepressants may be useful for the treatment of depression, alcohol dependence, or both, concurrently. Behavioral treatments are also effective in both<sup>159–161</sup>.

### 2.5 | LIVER DISEASES

Alcohol-related hepatotoxicity appears to be the “oldest form of liver injury known to humankind”<sup>162,163</sup>. Alcohol-related damage to the liver is broadly called alcoholic liver disease (ALD) and includes alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis<sup>164</sup>. About 90% of alcoholics develop alcoholic fatty liver (steatosis), about 25% develop alcoholic hepatitis, about 15% develop alcoholic cirrhosis, and about 10% develop hepatocellular carcinoma (HCC)<sup>165–168</sup>. Continued alcohol consumption usually leads to progression from alcoholic fatty liver to hepatitis and then on to cirrhosis. Alcoholic steatosis is usually asymptomatic (although some nausea, anorexia, and vomiting may be present)<sup>169</sup> and these patients exhibit mild elevations of gamma-glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels<sup>170</sup>. There is no abnormality of the serum bilirubin, International Normalized Ratio (INR), or albumin level. On liver biopsy, there



is microvesicular and macrovesicular fat accumulation within hepatocytes, minimal inflammatory reaction, and no hepatic fibrosis<sup>171</sup>. Abstinence will often revert these changes<sup>172</sup>. Patients with alcoholic hepatitis may have jaundice, pyrexia, unintentional weight loss, malnutrition, and an enlarged, tender liver<sup>173</sup>. There are moderate elevations in GGT, AST, and serum bilirubin<sup>174</sup>. Typically, the AST:ALT ratio is  $\geq 2:1$  in these patients<sup>175</sup>. The liver biopsy usually shows neutrophilic infiltration, hepatocyte necrosis, steatosis, and the presence of Mallory bodies<sup>176</sup>. Patients with alcoholic cirrhosis may also exhibit gynecomastia, palmar erythema, spider angiomas, testicular atrophy, parotid gland enlargement; signs of portal hypertension, and Dupuytren's contracture<sup>177</sup>. Laboratory findings often include hypoalbuminemia, hyperbilirubinemia, thrombocytopenia, and prolonged prothrombin time, and increased INR<sup>173</sup>. The liver biopsy usually reveals bridging fibrosis and regenerating nodules, and these are uniformly sized and micronodular<sup>178</sup>. In Western countries, alcohol is responsible for up to 50% of end-stage liver disease<sup>179</sup>. It is estimated that almost 50% of all deaths from cirrhosis in the world are related to ALD<sup>180</sup>. Potentiating factors for ALD include metabolic syndrome<sup>181</sup>, diabetes<sup>182</sup>, smoking<sup>183</sup>, obesity<sup>184</sup>, iron overload<sup>185</sup>, and chronic viral hepatitis B or C<sup>186,187</sup>. Genetic factors may also play a role<sup>188</sup>. Although abstinence markedly reduces mortality<sup>189</sup>, the only definitive treatment for ALD remains liver transplantation<sup>190–193</sup>. Alcohol abuse in patients with hepatitis B or HCV infection will often hasten the development of cirrhosis and its complications including HCC<sup>194</sup>. Alcohol abuse is reported to be responsible for approximately 15%–30% of HCC<sup>195,196</sup>.

### 3 | CONCLUSION

Alcohol drinking is popular all over the world. This manuscript focuses on the relationship between alcohol intake and cardiovascular diseases, obesity, respiratory diseases, depression, and liver disorders. Alcohol consumption is generally safe, provided the consumption is in low to moderate amounts. It appears to be beneficial in these amounts for CVDs.

However higher levels of alcohol consumption are harmful. Alcohol intake of more than 3 drinks per day in men and more than 2 drinks in women, should be avoided.

**Acknowledgment:** None

**Funding:** None

**Conflict of interest:** None

### REFERENCES

1. WHO. Noncommunicable diseases. 2018. <http://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>. Accessed 20 Sept 2020.
2. Kruk ME, Nigenda G, Knaul FM. Re-designing primary care to tackle the global epidemic of noncommunicable disease. *Am J Public Health*. 2015;105:431–437. doi: 10.2105/AJPH.2014.302392.
3. WHO. Noncommunicable diseases. 2018. <http://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>. Accessed 20 Sept 2020.
4. WHO. Noncommunicable diseases: the slow-motion disaster. 2017.
5. NCD Alliance. The financial burden of NCDs. <https://ncdalliance.org/why-ncds/the-financial-burden-of-ncds>. Accessed 11 Dec 2020.
6. United Nations Transforming our world: the 2030 agenda for sustainable development. <http://sdgs.un.org/sites/default/files/publications/2020/2020Agenda%20for%20Sustainable%20Development%20web.pdf>.
7. O'Keefe E.L., DiNicolantonio J.J., O'Keefe J.H., Lavie C.J. Alcohol and CV Health: Jekyll and Hyde J-Curves. *Prog. Cardiovasc. Dis*. 2018;61:68–75. doi: 10.1016/j.pcad.2018.02.001.
8. Piano M.R. Alcohol's Effects on the Cardiovascular System. *Alcohol Res*. 2017;38:219–241.
9. Alcohol Research: Current Reviews Editorial Staff. Drinking Patterns and Their Definitions. *Alcohol Res*. 2018;39(1):17-18.

ALCOHOL AND NONCOMMUNICABLE DISEASES: PART I CARDIOVASCULAR DISEASES, OBESITY, RESPIRATORY DISEASES, DEPRESSION, LIVER DISEASES

10. Alcohol Facts and Statistics In: Alcoholism NIAAA, editor.2017.
11. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: A statement by the American Society of Hypertension and the International Society of Hypertension. *Journal of Clinical Hypertension (Greenwich)* 2014;16(1):14–26.
12. Xi B., Veeranki S.P., Zhao M., Ma C., Yan Y., Mi J. Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults. *J. Am. Coll. Cardiol.* 2017;70:913–922. doi: 10.1016/j.jacc.2017.06.054.
13. Fernández-Solà J. Cardiovascular risks and benefits of moderate and heavy alcohol consumption. *Nat. Rev. Cardiol.* 2015;12:576–587. doi: 10.1038/nrcardio.2015.91.
14. Kuntsche E., Kuntsche S., Thrul J., Gmel G. Binge drinking: Health impact, prevalence, correlates and interventions. *Psychol. Health.* 2017;32:976–1017. doi: 10.1080/08870446.2017.1325889.
15. Fillmore M.T., Jude R. Defining “binge” drinking as five drinks per occasion or drinking to a .08% BAC: Which is more sensitive to risk? *Am. J. Addict.* 2011;20:468–475. doi: 10.1111/j.1521-0391.2011.00156.x.
16. Esser MB, Hedden SL, Kanny D, Brewer RD, Gfroerer JC, Naimi TS. Prevalence of Alcohol Dependence Among US Adult Drinkers, 2009–2011. *Prev Chronic Dis* 2014;11:140329.
17. <https://www.niaaa.nih.gov/>.
18. European Association for the study of the liver EASL Clinical practice guidelines: Management of alcohol-related liver disease. *J Hepatol*, 69 (2018), pp. 154-181 Accessed 1/11/2018 at <https://doi.org/10.1016/j.jhep.2018.03.018>.
19. World Health Organization. Global status report on alcohol and health—2018 external icon. Geneva, Switzerland: World Health Organization; 2018.; International Agency for Research on Cancer. Personal Habits and Indoor Combustions: A Review of Human Carcinogens, Volume 100E 2012. Available from: <http://monographs.iarc.fr/ENG/Monographs/vol100E/index.phpexternal icon>.
20. World Health Organization. Global status report on alcohol and health—2018. Geneva, Switzerland: World Health Organization; 2018.
21. Miller JW, Naimi TS, Brewer RD, Jones SE. Binge drinking and associated health risk behaviors among high school students. *Pediatrics.* 2007;119(1):76-85.
22. Castaneda R, Sussman N, Westreich L, Levy R, O’Malley M. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders. *J Clin Psychiatry* 1996;57(5):207–212.
23. Smith GS, Branas CC, Miller TR. Fatal nontraumatic injuries involving alcohol: a metaanalysis. *Ann of Emer Med* 1999;33(6):659–668.
24. Smith GS, Branas CC, Miller TR. Fatal nontraumatic injuries involving alcohol: a metaanalysis external icon. *Ann of Emer Med* 1999;33(6):659–668.
25. Greenfield LA. Alcohol and Crime: An Analysis of National Data on the Prevalence of Alcohol Involvement in Crime. Report prepared for the Assistant Attorney General’s National Symposium on Alcohol Abuse and Crime. Washington, DC: U.S. Department of Justice, 1998.
26. Mohler-Kuo M, Dowdall GW, Koss M, Wechsler H. Correlates of rape while intoxicated in a national sample of college women. *Journal of Studies on Alcohol* 2004;65(1):37–45.
27. Abbey A. Alcohol-related sexual assault: a common problem among college students. *J Stud Alcohol Suppl.* 2002 Mar;(14):118-28. doi: 10.15288/jsas.2002.s14.118.

28. Naimi TS, Lipscomb LE, Brewer RD, Colley BG. Binge drinking in the preconception period and the risk of unintended pregnancy: Implications for women and their children. *Pediatrics* 2003;11(5):1136–1141.
29. Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Sechler NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. *Alcohol & Alcoholism* 2002;37(1):87–92.
30. American Academy of Pediatrics, Committee on Substance Abuse and Committee on Children with Disabilities. 2000. Fetal alcohol syndrome and alcohol-related neurodevelopmental disorders. *Pediatrics* 2000;106:358–361.
31. Kanny D, Brewer RD, Mesnick JB, Paulozzi LJ, Naimi TS, Lu H. Vital Signs: Alcohol Poisoning Deaths — United States, 2010–2012. *MMWR* 2015;63:1238-1242.
32. Poznyak V, Fleischmann A, Rekke D, Rylett M, Rehm J, Gmel G. The world health organization's global monitoring system on alcohol and health. *Alcohol Res.* (2013) 35:244–9.
33. [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)) – accessed August 4, 2021.
34. WHO, The Top 10 Causes of Death, <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>, - Accessed date: 20 June 201;
35. <https://www.afro.who.int/health-topics/cardiovascular-diseases> - accessed July 30, 2021.
36. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. *Journal of the American College of Cardiology.* 2017; 70(1): 1–25. DOI: 10.1016/j.jacc.2017.04.052.
37. Noncommunicable Diseases Country Profiles 2018. Geneva: World Health Organization; 2018, 223. Available online: <https://www.who.int/nmh/publications/ncd-profiles-2018/en>.
38. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med.* 2020 Jun;8(6):585-596. doi: 10.1016/S2213-2600(20)30105-3.
39. Mandell LA. Community-acquired pneumonia: An overview. *Postgrad Med.* 2015 Aug;127(6):607-15. doi: 10.1080/00325481.2015.1074
40. World Health Organizationc1948. Tuberculosis fact sheet. Geneva (Switzerland): WHO global TB programme (2014 Oct). Available from: <http://www.who.int/mediacentre/factsheets/fs104/en/>.
41. Executive summary. *Obes. Res.* 1998.6, 51S-179S. doi: 10.1002/j.1550-8528.1998.tb00690.x.
42. Hales C. M., Carroll M. D., Fryar C. D., Ogden C. L. (2017). Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018 Key Findings Data from the National Health and Nutrition Examination Survey. Available online at: <https://www.cdc.gov/nchs/products/index.htm> -accessed April 1, 2020.
43. Must A., McKeown N. M. (2000). The Disease Burden Associated with Overweight and Obesity. MDText.com, Inc. Available online at: <http://www.ncbi.nlm.nih.gov/pubmed/25905320> (accessed July 30, 2021).
44. Allison D. B., Fontaine K. R., Manson J. A. E., Stevens J., VanItallie T. B. (1999). Annual deaths attributable to obesity in the United States. *J. Am. Med. Assoc.* 282, 1530–1538. 10.1001/jama.282.16.1530.
45. La Sala L, Pontiroli AE. Prevention of Diabetes and Cardiovascular Disease in Obesity. *Int J Mol Sci.* 2020 Oct 31;21(21):8178. doi: 10.3390/ijms21218178.
46. Almeida OP. Prevention of depression in older age. *Maturitas.* 2014 Oct;79(2):136-41. doi: 10.1016/j.maturitas.2014.03.005.

ALCOHOL AND NONCOMMUNICABLE DISEASES: PART I CARDIOVASCULAR DISEASES, OBESITY, RESPIRATORY DISEASES, DEPRESSION, LIVER DISEASES

47. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. *Nat. Neurosci.* 2007;10(9):1116–1124. doi: 10.1038/nn1944.
48. Byers A.L., Yaffe K. Depression and risk of developing dementia. *Nat. Rev. Neurol.* 2011;7(6):323–331. doi: 10.1038/nrneurol.2011.60.
49. Knol M.J., Twisk J.W., Beekman A.T., Heine R.J., Snoek F.J., Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. *Diabetologia.* 2006;49(5):837–845. doi: 10.1007/s00125-006-0159-x.
50. Bucciarelli V, Caterino AL, Bianco F, Caputi CG, Salerni S, Sciomer S, Maffei S, Gallina S. Depression and cardiovascular disease: The deep blue sea of women’s heart. *Trends Cardiovasc Med.* 2020 Apr;30(3):170-176. doi: 10.1016/j.tcm.2019.05.001.
51. Depression and Parkinson’s disease: current knowledge. *Curr Neurol Neurosci Rep.* 2013 Dec;13(12):409. doi: 10.1007/s11910-013-0409-5.
52. Henning O, Nakken KO. Epilepsi og depresjon [Epilepsy and depression]. *Tidsskr Nor Laegeforen.* 2011 Jul 1;131(13-14):1298-301. Norwegian. doi: 10.4045/tidsskr.10.0739.
53. Zis P, Daskalaki A, Bountouni I, Sykioti P, Varrassi G, Paladini A. Depression and chronic pain in the elderly: links and management challenges. *Clin Interv Aging.* 2017 Apr 21;12:709-720. doi: 10.2147/CIA.S113576.
54. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. *Psychol Med.* 2010 Nov;40(11):1797-810. doi: 10.1017/S0033291709992285.
55. Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. *Osteoporos Int.* 2008 Jan;19(1):1-12. doi: 10.1007/s00198-007-0449-2.
56. Mudyadzo TA, Hauzaree C, Yerokhina O, Architha NN, Ashqar HM. Irritable Bowel Syndrome and Depression: A Shared Pathogenesis. *Cureus.* 2018 Aug 21;10(8):e3178. doi: 10.7759/cureus.3178.
57. Williams R. Global challenges in liver disease. *Hepatology.* 2006 Sep;44(3):521-6. doi: 10.1002/hep.21347.
58. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. *Clin Microbiol Rev.* 2020 Feb 26;33(2):e00046-19. doi: 10.1128/CMR.00046-19.
59. Applegate TL, Fajardo E, Sacks JA. Hepatitis C Virus Diagnosis and the Holy Grail. *Infect Dis Clin North Am.* 2018 Jun;32(2):425-445. doi: 10.1016/j.idc.2018.02.010.
60. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol.* 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109.
61. Hosseini N, Shor J, Szabo G. Alcoholic Hepatitis: A Review. *Alcohol Alcohol.* 2019 Jul 1;54(4):408-416. doi: 10.1093/alcalc/aggz036.
62. Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. *Korean J Intern Med.* 2017 Mar;32(2):213-228. doi: 10.3904/kjim.2016.268.
63. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet.* 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2.
64. Goel S, Sharma A, Garg A. Effect of Alcohol Consumption on Cardiovascular Health. *Curr Cardiol Rep.* 2018 Mar 8;20(4):19. doi: 10.1007/s11886-018-0962-2.
65. O’Keefe JH, Bhatti SK, Bajwa A, et al. Alcohol and cardiovascular health: the dose makes the poison...or the remedy. *Mayo Clin Proc* 2014; 89: 382–393.



66. O'Keefe EL, DiNicolantonio JJ, O'Keefe JH, et al. Alcohol and CV health: Jekyll and Hyde J-curves. *Prog Cardiovasc Dis* 2018; 61: 68–75.
67. Kuntsche E., Kuntsche S., Thrul J., Gmel G. Binge drinking: Health impact, prevalence, correlates and interventions. *Psychol. Health.* 2017;32:976–1017. doi: 10.1080/08870446.2017.1325889.
68. National Institute on Alcohol Abuse Alcoholism NIH. (2020). Turning Discovery Into Health<sup>®</sup> National Institute on Alcohol Abuse and Alcoholism Alcohol Facts and Statistics. Available online at: <https://www.niaaa.nih.gov> (accessed March 30, 2020).
69. Milon H, Froment A, Gaspard P, Guidollet J, Ripoll JP. Alcohol consumption and blood pressure in a French epidemiological study. *Eur Heart J.* 1982;3 Suppl C:59–64.
70. Friedman GD, Klatsky AL, Siegelaub AB. Alcohol intake and hypertension. *Ann Intern Med.* 1983;98:846–849.
71. MacMahon S. Alcohol consumption and hypertension. *Hypertension.* 1987;9:111–121.
72. Potter JF, Watson RD, Skan W, Beevers DG. The pressor and metabolic effects of alcohol in normotensive subjects. *Hypertension.* 1986;8(7):625–631.
73. Rosito GA, Fuchs FD, Duncan BB. Dose-dependent biphasic effect of ethanol on 24-h blood pressure in normotensive subjects. *American Journal of Hypertension.* 1999;12(2 Pt 1):236–240.
74. Seppä K, Sillanaukee P. Binge drinking and ambulatory blood pressure. *Hypertension.* 1999;33(1):79–82.
75. Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. *Lancet Public Health.* 2017;2:e108–e120. doi: 10.1016/S2468-2667(17)30003-8.
76. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. *BMJ.* 2011;342:d671.
77. Bagnardi V, Zatonski W, Scotti L, La Vecchia C, Corrao G. Does drinking pattern modify the effect of alcohol on the risk of coronary heart disease? Evidence from a meta-analysis. *J Epidemiol Community Health* 2008;62:615-9. doi:10.1136/jech.2007.065607.
78. Larsson SC, Wallin A, Wolk A, Markus HS. Differing association of alcohol consumption with different stroke types: a systematic review and meta-analysis. *BMC Med.* 2016;14(1):178. Published 2016 Nov 24. doi:10.1186/s12916-016-0721-4.
79. Larsson SC, Orsini N, Wolk A. Alcohol consumption and risk of heart failure: A dose-response meta-analysis of prospective studies. *European Journal of Heart Failure.* 2015;17(4):367–373.
80. Wannamethee SG, Whincup PH, Lennon L, et al. Alcohol consumption and risk of incident heart failure in older men: A prospective cohort study. *Open Heart.* 2015;2(1):e000266.
81. Fernández-Solà J. The Effects of Ethanol on the Heart: Alcoholic Cardiomyopathy. *Nutrients.* 2020;12:572. doi: 10.3390/nu12020572.
82. Lowenstein SR, Gabow PA, Cramer J, Oliva PB, Ratner K. The role of alcohol in new-onset atrial fibrillation. *Arch Intern Med.* 1983 Oct;143(10):1882-5.
83. Csengeri D., Sprünker N.A., Di Castelnuovo A. et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. *Eur. Heart J.* 2021;42:1170–1177. doi: 10.1093/eurheartj/ehaa953.
84. Koskinen P, Kupari M, Leinonen H, Luomanmäki K. Alcohol and new onset atrial fibrillation: a case-control study of a current series. *Br Heart J.* 1987 May;57(5):468-73.

ALCOHOL AND NONCOMMUNICABLE DISEASES: PART I CARDIOVASCULAR DISEASES, OBESITY, RESPIRATORY DISEASES, DEPRESSION, LIVER DISEASES

85. Hietanen S, Herajärvi J, Junttila J, Pakanen L, Huikuri HV, Liisanantti J. Characteristics of subjects with alcoholic cardiomyopathy and sudden cardiac death. *Heart*. 2020 May;106(9):686-690. doi: 10.1136/heartjnl-2019-315534.
86. Perkiömäki J, Hookana E, Kaikkonen K, Junttila J, Kortelainen ML, Huikuri H. Blood alcohol in victims of sudden cardiac death in northern Finland. *Europace*. 2016 Jul;18(7):1006-9. doi: 10.1093/europace/euv341.
87. Chen Z, Li S, Guo L, Peng X, Liu Y. Prenatal alcohol exposure induced congenital heart diseases: From bench to bedside. *Birth Defects Res*. 2020 Jun 24. doi: 10.1002/bdr2.1743.
88. Denny L, Coles S, Blitz R. Fetal Alcohol Syndrome and Fetal Alcohol Spectrum Disorders. *Am Fam Physician*. 2017 Oct 15;96(8):515-522.
89. Xie X, Ma YT, Yang YN, et al. Alcohol consumption and ankle-to-brachial index: Results from the Cardiovascular Risk Survey. *PLoS One*. 2010;5(12):e15181.
90. Wang XM, Bai YJ, Yang YB, Li JH, Tang Y, Han P. Alcohol intake and risk of erectile dysfunction: a dose-response meta-analysis of observational studies. *Int J Impot Res*. 2018 Nov;30(6):342-351. doi: 10.1038/s41443-018-0022-x. Epub 2018 Sep 19. PMID: 30232467.
91. Chakravorty S, Chaudhary NS, Brower KJ. Alcohol Dependence and Its Relationship With Insomnia and Other Sleep Disorders. *Alcohol Clin Exp Res*. 2016 Nov;40(11):2271-2282. doi: 10.1111/acer.13217.
92. Pan CS, Ju TR, Lee CC, Chen YP, Hsu CY, Hung DZ, Chen WK, Wang IK. Alcohol use disorder tied to development of chronic kidney disease: A nationwide database analysis. *PLoS One*. 2018 Sep 6;13(9):e0203410. doi: 10.1371/journal.pone.0203410.
93. Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. *Nutr Rev*. 2011 Aug;69(8):419-31. doi: 10.1111/j.1753-4887.2011.00403.x.
94. Boden JM, Fergusson DM. Alcohol and depression. *Addiction*. 2011 May;106(5):906-14. doi: 10.1111/j.1360-0443.2010.03351.x.
95. Stamler J, Caggiula AW, Grandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. *Am J Clin Nutr* 1997;65: 1 suppl: 338s–65s.
96. Knott C, Bell S, Britton A. Alcohol Consumption and the Risk of Type 2 Diabetes: A Systematic Review and Dose-Response Meta-analysis of More Than 1.9 Million Individuals From 38 Observational Studies. *Diabetes Care*. 2015 Sep;38(9):1804-12. doi: 10.2337/dc15-0710.
97. Mori T.A., Burke V., Beilin L.J., Puddey I.B. Randomized Controlled Intervention of the Effects of Alcohol on Blood Pressure in Premenopausal Women. *Hypertension*. 2015;66:517–523. doi: 10.1161/HYPERTENSIONAHA.115.05773.
98. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. *New Engl J Med* 1993;329:1829–1834.
99. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. *BMJ* 1999;319:1523–1528.
100. Gisbertz SS, Derksen WJ, de Kleijn DP, Vink A, Bots ML, de Vries JP, Moll FL, Pasterkamp G. The effect of alcohol on atherosclerotic plaque composition and cardiovascular events

- in patients with arterial occlusive disease. *J Vasc Surg* 2011;54:123–131.
101. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. *Clin Chim Acta*, (2):207-219 19957.
  102. Dimmitt SB, Rakic V, Puddey IB, et al. The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial. *Blood Coagul Fibrinolysis*, (1):39-45 19988-10), factor VII (FVII), von Willebrand factor (vWF).
  103. Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. *Circulation*, (12):1367-1373 200110.
  104. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. *Arterioscler Thromb Vasc Biol*, (1):271-279 2000.MED: 10634829.
  105. Sayon-Orea C, Martinez-Gonzalez MA, Bes-Rastrollo M. Alcohol consumption and body weight: a systematic review. *Nutr Rev*. 2011;69:419–31. doi: 10.1111/j.1753-4887.2011.00403.x.
  106. Gruchow HW, Sobocinski KA, Barboriak J, et al. Alcohol consumption, nutrient intake and relative body weight among US adults. *Am J Clin Nutr*. 1985;42:289–95.
  107. Traversy, G & Chaput, JP (2015) Alcohol consumption and obesity: an update. *Curr Obes Rep* 4, 122–130.
  108. Yeomans MR. Alcohol, appetite and energy balance: is alcohol intake a risk factor for obesity? *Physiol Behav*. 2010 Apr 26;100(1):82-9. doi: 10.1016/j.physbeh.2010.01.012.
  109. Nielsen SJ, Kit BK, Fakhouri T, Ogden CL. Calories Consumed From Alcoholic Beverages by U.S. Adults, 2007–2010. NCHS Data Brief, no 110. Hyattsville, MD: National Center for Health Statistics; 2012: 1–8.
  110. MacInnis RJ, Hodge AM, Dixon HG, et al. Predictors of increased body weight and waist circumference for middle-aged adults. *Public Health Nutr*. 2014;17:1087–97. doi: 10.1017/S1368980013001031.
  111. Sayon-Orea C, Bes-Rastrollo M, Nuñez-Corboda JM, Basterra-Gortari FJ, Beunza JJ, Martinez-Gonzalez MA. Type of alcoholic beverage and incidence of overweight/obesity in a Mediterranean cohort: The SUN project. *Nutrition*. 2011;27:802–8. doi: 10.1016/j.nut.2010.08.023.
  112. Schütze M, Schulz M, Steffen A, et al. Beer consumption and the 'beer belly': scientific basis or common belief? *Eur J Clin Nutr*. 2009;63:1143–9. doi: 10.1038/ejcn.2009.39.
  113. French, MT, Popovici, I & Maclean, JC (2009) Do alcohol consumers exercise more? Findings from a national survey. *Am J Health Promot* 24, 2–10.
  114. Kim, BY., Nam, H., Yoo, JJ. et al. Association between alcohol consumption status and obesity-related comorbidities in men: data from the 2016 Korean community health survey. *BMC Public Health* 21, 733 (2021). <https://doi.org/10.1186/s12889-021-10776-y>.
  115. Nielsen SJ, Kit BK, Fakhouri T, Ogden CL. Calories Consumed From Alcoholic Beverages by U.S. Adults, 2007–2010. NCHS Data Brief, no 110. Hyattsville, MD: National Center for Health Statistics; 2012: 1–8.
  116. Bendsen NT, Christensen R, Bartels EM, et al. Is beer consumption related to measures of abdominal and general obesity? A systematic review and meta-analysis. *Nutr Rev*. 2013;71:67–87. doi: 10.1111/j.1753-4887.2012.00548.x.

ALCOHOL AND NONCOMMUNICABLE DISEASES: PART I CARDIOVASCULAR DISEASES, OBESITY, RESPIRATORY DISEASES, DEPRESSION, LIVER DISEASES

117. GBD 2015 Risk Factors Collaborators (2016) Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 388, 1659–1724.
118. Robinson E., Roberts C., Vainik U., Jones A. (2020). The psychology of obesity: an umbrella review and evidence-based map of the psychological correlates of heavier body weight. *Neurosci. Biobehav. Rev.* 119, 468–480. [10.1016/j.neubiorev.2020.10.009](https://doi.org/10.1016/j.neubiorev.2020.10.009).
119. Bonnet, F., Disse, E., Laville, M. et al. Moderate alcohol consumption is associated with improved insulin sensitivity, reduced basal insulin secretion rate and lower fasting glucagon concentration in healthy women. *Diabetologia* 55, 3228–3237 (2012). <https://doi.org/10.1007/s00125-012-2701-3>.
120. O'Donovan, G., Stamatakis, E., & Hamer, M. (2018). Associations between alcohol and obesity in more than 100 000 adults in England and Scotland. *British Journal of Nutrition*, 119(2), 222–227. [doi:10.1017/S000711451700352X](https://doi.org/10.1017/S000711451700352X).
121. Kaluza J, Harris HR, Linden A, Wolk A. Alcohol Consumption and Risk of Chronic Obstructive Pulmonary Disease: A Prospective Cohort Study of Men. *Am J Epidemiol.* 2019 May 1;188(5):907-916. [doi: 10.1093/aje/kwz020](https://doi.org/10.1093/aje/kwz020).
122. Ayres JG, Clark TJ. Alcoholic drinks and asthma: a survey. *Br J Dis Chest.* 1983 Oct;77(4):370-5.
123. Freudenheim JL, Ritz J, Smith-Warner SA, Albanes D, Bandera EV, van den Brandt PA, Colditz G, Feskanich D, Goldbohm RA, Har-nack L, Miller AB, Rimm E, Rohan TE, Sellers TA, Virtamo J, Willett WC, Hunter DJ. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. *Am J Clin Nutr.* 2005 Sep;82(3):657-67.
124. Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Liñares J, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. *Thorax.* 2010;65:77–81.
125. Mehta AJ, Guidot DM. Alcohol abuse, the alveolar macrophage and pneumonia. *American Journal of the Medical Sciences.* 2012;343(3):244–247.
126. Happel KI, Nelson S. Alcohol, immunosuppression, and the lung. *Proceedings of the American Thoracic Society.* 2005;2(5):428–432.
127. Perlino CA, Rimland D. Alcoholism, leukopenia, and pneumococcal sepsis. *The American Review of Respiratory Disease.* 1985;132(4):757–760.
128. Jong G-M, Hsiue T-R, Chen C-R, et al. Rapidly fatal outcome of bacteremic *Klebsiella pneumoniae* pneumonia in alcoholics. *Chest.* 1995;107(1):214–217.
129. Plevneshi A, Svoboda T, Armstrong I, Tyrrell GJ, Miranda A, Green K, et al. Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. *PLoS One.* 2009;4:e7255.
130. Moss M, Bucher B, Moore FA, Moore EE, Parsons PE. The role of chronic alcohol abuse in the development of acute respiratory distress syndrome in adults. *JAMA.* 1996;275:50–54.
131. Adamuz J, Viasus D, Camprecios-Rodriguez P, et al. A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. *Respirology.* 2011;16(7):1119–1126.
132. Moss M, Burnham EL. Chronic alcohol abuse, acute respiratory distress syndrome, and multiple organ dysfunction. *Crit Care Med* 31, Suppl: S207–S212, 2003. [doi:10.1097/01.CCM.0000057845.77458.25](https://doi.org/10.1097/01.CCM.0000057845.77458.25).



133. Clark BJ, Williams A, Feemster LM, Bradley KA, Macht M, Moss M, Burnham EL; NHLBI ARDS Network Investigators. Alcohol screening scores and 90-day outcomes in patients with acute lung injury. *Crit Care Med* 41: 1518–1525, 2013. doi:10.1097/CCM.0b013e318287f1bb.
134. Merrick EL, Hodgkin D, Garnick DW, Horgan CM, Panas L, Ryan M, Saitz R, Blow FC. Unhealthy drinking patterns and receipt of preventive medical services by older adults. *J Gen Intern Med*. 2008 Nov;23(11):1741-8. doi: 10.1007/s11606-008-0753-3.
135. Luján M, Burgos J, Gallego M, Falcó V, Bermudo G, Planes A, et al. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. *Clinical Infectious Diseases*. 2013;57:1722–1730.
136. Borgdorff MW, Veen J, Kalisvaart NA, Nagelkerke N. Mortality among tuberculosis patients in the Netherlands in the period 1993–1995. *European Respiratory Journal*. 1998;11(4):816–820.
137. Jerrells TR, Pavlik JA, DeVasure J, et al. Association of chronic alcohol consumption and increased susceptibility to and pathogenic effects of pulmonary infection with respiratory syncytial virus in mice. *Alcohol*. 2007;41(5):357–369.
138. Moss M, Burnham EL. Chronic alcohol abuse, acute respiratory distress syndrome, and multiple organ dysfunction. *Critical Care Medicine*. 2003;31(Suppl. 4):S207–S212.
139. Liffner G, Bak Z, Reske A, Sjöberg F. Inhalation injury assessed by score does not contribute to the development of acute respiratory distress syndrome in burn victims. *Burns*. 2005;31:263–268.
140. Cook RT. Alcohol abuse, alcoholism, and damage to the immune system: A review. *Alcoholism: Clinical and Experimental Research*. 1998;22:1927–1942.
141. Samuelson DR, Burnham EL, Maffei VJ, Vandivier RW, Blanchard EE, Shellito JE, Luo M, Taylor CM, Welsh DA. The respiratory tract microbial biogeography in alcohol use disorder. *Am J Physiol Lung Cell Mol Physiol*. 2018 Jan 1;314(1):L107-L117. doi: 10.1152/ajplung.00277.2017.
142. Berkowitz H, Reichel J, Shim C. The effect of ethanol on the cough reflex. *Clin Sci Mol Med* 45: 527–531, 1973.; Joshi PC, Guidot DM. The alcoholic lung: Epidemiology, pathophysiology, and potential therapies. *American Journal of Physiology Lung Cellular and Molecular Physiology*. 2007;292(4):L813–L823.2012.
143. Simet SM, Sisson JH. Alcohol's Effects on Lung Health and Immunity. *Alcohol Res*. 2015;37(2):199-208.
144. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry*. 2004;61(8):807–816.
145. Guertler D, Moehring A, Krause K, Batra A, Eck S, Freyer-Adam J, Ulbricht S, Rumpf HJ, Bischof G, John U, Meyer C. Copattern of depression and alcohol use in medical care patients: cross-sectional study in Germany. *BMJ Open*. 2020 May 6;10(5):e032826. doi: 10.1136/bmjopen-2019-032826.
146. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. *JAMA Psychiatry*. 2015;72(8):757–766.
147. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Arch Gen Psychiatry*. 2005;62(10):1097–1106.
148. Foster KT, Hicks BM, Iacono WG, et al. Gender differences in the structure of risk for alcohol

ALCOHOL AND NONCOMMUNICABLE DISEASES: PART I CARDIOVASCULAR DISEASES, OBESITY, RESPIRATORY DISEASES, DEPRESSION, LIVER DISEASES

- use disorder in adolescence and young adulthood. *Psychol Med.* 2015;45(14):3047–3058.
149. Bell S, Britton A, Kubinova R, et al. Drinking pattern, abstention and problem drinking as risk factors for depressive symptoms: evidence from three urban eastern European populations. *PLoS One* 2014;9:e104384. 10.1371/journal.pone.0104384.
150. Bellos S, Skapinakis P, Rai D, et al. Longitudinal association between different levels of alcohol consumption and a new onset of depression and generalized anxiety disorder: results from an international study in primary care. *Psychiatry Res* 2016;243:30–4. 10.1016/j.psychres.2016.05.049.
151. Abraham HD, Fava M. Order of onset of substance abuse and depression in a sample of depressed outpatients. *Compr Psychiatry.* 1999;40(1):44–50.
152. Fergusson DM, Boden JM, Horwood LJ. Tests of causal links between alcohol abuse or dependence and major depression. *Arch Gen Psychiatry.* 2009;66(3):260–266.
153. Greenfield SF, Weiss RD, Muenz LR, et al. The effect of depression on return to drinking: A prospective study. *Arch Gen Psychiatry.* 1998;55(3):259–265.
154. Hasin D, Liu X, Nunes E, et al. Effects of major depression on remission and relapse of substance dependence. *Arch Gen Psychiatry.* 2002;59(4):375–380.
155. Hanna EZ, Grant BF. Gender differences in DSM-IV alcohol use disorders and major depression as distributed in the general population: Clinical implications. *Compr Psychiatry.* 1997;38(4):202–212.
156. Prescott CA, Aggen SH, Kendler KS. Sex-specific genetic influences on the comorbidity of alcoholism and major depression in a population-based sample of U.S. twins. *Arch Gen Psychiatry.* 2000;57(8):803–811.
157. Boden JM, Fergusson DM. Alcohol and depression. *Addiction.* 2011;106(5):906–914. doi:10.1111/j.1360-0443.2010.03351.x.
158. Liappas J, Paparrigopoulos T, Tzavellas E, et al. Impact of alcohol detoxification on anxiety and depressive symptoms. *Drug Alcohol Depend.* 2002;68(2):215–220.
159. Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. *Cochrane Database Syst Rev.* 2018 Apr 24;4(4):CD008581. doi:10.1002/14651858.CD008581.pub2.
160. McCarter KL, Halpin SA, Baker AL, et al. Associations between personality disorder characteristics and treatment outcomes in people with co-occurring alcohol misuse and depression. *BMC Psychiatry.* 2016;16:210. Published 2016 Jul 7. doi:10.1186/s12888-016-0937-z.
161. Andrews G, editor. *Management of Mental Disorders.* 4. Sydney: The World Health Organization Collaborating Centre for Mental Health and Substance Abuse; 2004.
162. O’Shea R.S., Dasarathy S., McCullough A.J. the Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology. *Alcoholic Liver Disease.Hepatology,* 51 (2010), pp. 307-328.
163. Singal A.K., Anand B.S. Recent Trends in the Epidemiology of Alcoholic Liver Disease. *Clin Liv Dis,* 2 (2013), pp. 53-56.
164. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. *Am J Gastroenterol.* 2018;113(2):175-194. doi:10.1038/ajg.2017.469.
165. Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. *J Gastroenterol Hepatol.* 2013;28 Suppl 1:77–84.

166. Mann RE, Smart RG, Govoni R. The epidemiology of alcoholic liver disease. *Alcohol Res Health*. 2003;27:209–219.
167. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. *Semin Liver Dis*. 1986;6:221–232.
168. O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. *Clin Liver Dis*. 2005;9:103–134.
169. Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. *N Engl J Med* 1968; 278 : 869–76.
170. Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. *Best Pract Res Clin Gastroenterol*. 2013;27:577–596.
171. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. *Semin Liver Dis*. 1986;6:221–232.
172. Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. *Best Pract Res Clin Gastroenterol*. 2013;27:577–596.
173. European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol*. 2012;57:399–420.
174. Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. *Best Pract Res Clin Gastroenterol*. 2013;27:577–596.
175. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. *Am J Gastroenterol*. 1999;94:1018–1022.
176. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. *Semin Liver Dis*. 1986;6:221–232.
177. Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, Etienne JP. Dupuytren’s contracture, alcohol consumption, and chronic liver disease. *Arch Intern Med*. 1987;147:1065–1067.
178. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. *Semin Liver Dis*. 1986;6:221–232.
179. Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. *Therap Adv Gastroenterol*. (2011) 4:63–81. 10.1177/1756283X10378925.
180. Liangpunsakul S., Haber P., McCaughan. Alcoholic Liver Disease in Asia, Europe, and North America. *Gastroenterology*, 150 (2016), pp. 1786-1797. Doi: 10.1053/j.gastro.2016.02.043.
181. Park EY, Lim MK, Oh JK, Cho H, Bae MJ, Yun EH, Kim DI, Shin HR. Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. *PLoS One*. 2013;8:e63439.
182. Taniai M, Hashimoto E, Tokushige K, Kodama K, Kogiso T, Torii N, Shiratori K. Roles of gender, obesity, and lifestyle-related diseases in alcoholic liver disease: Obesity does not influence the severity of alcoholic liver disease. *Hepatol Res*. 2012;42:359–367.
183. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. *Hepatology*. 1997;25:108–111.
184. Park EY, Lim MK, Oh JK, Cho H, Bae MJ, Yun EH, Kim DI, Shin HR. Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. *PLoS One*. 2013;8:e63439.
185. Fletcher LM, Halliday JW, Powell LW. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. *J Gastroenterol Hepatol*. 1999;14:202–214.

186. Schmidt CS, Schön D, Schulte B, Lüth S, Polywka S, Reimer J. Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake. *J Addict Med*. 2013;7:417–421.
187. Zhang M, Wu R, Jiang J, Minuk GY, Niu J. The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis. *Alcohol*. 2013;47:553–558.
188. Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. *Alcohol Clin Exp Res* 1981;5:207–15.
189. Xie, Y.-D., Feng, B., Gao, Y. and Wei, L. (2014), Alcohol abstinence and survival. *Hepatol Res*, 44: 436-449. <https://doi.org/10.1111/hepr.12131>.
190. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry) *Am J Transplant*. 2010;10:138–148.
191. Singal AK, Guturu P, Hmoud B et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. *Transplantation* 2013;95:755–60.
192. Adam R, Karam V, Delvart V et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012;57:675–88.
193. Burra P, Senzolo M, Adam R et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant* 2010;10:138–48.
194. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METaViR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997;349:825–32.
195. Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: a review and a point of view. *World J Gastroenterol* 2014;20:15943–54. [10.3748/wjg.v20.i43.15943](https://doi.org/10.3748/wjg.v20.i43.15943).
196. Hlady RA, Tiedemann RL, Puszyk W, et al. . Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. *Oncotarget* 2014;5:9425–43. [10.18632/oncotarget.2444](https://doi.org/10.18632/oncotarget.2444).

**How to cite this article:** Agarwal S.K, MD. **Alcohol and Noncommunicable Diseases: Part I Cardiovascular Diseases, Obesity, Respiratory Diseases, Depression, Liver Diseases**. *Clinical Medicine Insights*. 2021;169–184. <https://doi.org/10.52845/CMI/2021-2-3-5>